Skip to content

Overcoming Learned Non-Use in Chronic Aphasia

Overcoming Learned Non-Use in Chronic Aphasia: Behavioral, fMRI and QoL Outcomes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02012374
Enrollment
24
Registered
2013-12-16
Start date
2012-02-26
Completion date
2015-07-09
Last updated
2022-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke-induced Aphasia

Keywords

aphasia, anomia, speech therapy, rehabilitation, neuroplasticity, fMRI, quality of life

Brief summary

In this study the investigators are examining the effectiveness of intensive speech therapy in chronic moderate-to-severe stroke-induced aphasia under two conditions - responses constrained or unconstrained to speech. Both treatments involve massed practice communicating, using intensive language action therapy 3 hours/day, 5 days/week for two weeks, followed by six months of a home practice program. One treatment stresses spoken responses as the preferred expressive modality during intensive therapy. Before and after treatment, and following the home practice program and a period of no practice, the investigators will administer several tests and discourse samples to examine changes associated with the treatments. Participants will also undergo structural and functional MRI testing at these time points. The investigators will also attempt to quantify the degree to which improvements following intensive language therapy and home practice correlate with changes in Quality of Life measures as perceived by both participants with aphasia and their significant others. It is hypothesized that, whereas both treatments will lead to improvements in naming practiced words and communicating, outcomes will be enhanced for the group randomly assigned to the constraint condition. Moreover, performance will be enhanced on words practiced during the home practice program, including those that were not practiced during intensive therapy. Improved naming will correlate with modulation of 'signature' language and attentional networks, whose variability will depend on remaining viable brain structures. Initial severity and site/extent of lesion should predict patients' ability to transfer gains in naming to improvements in discourse.

Interventions

BEHAVIORALIntensive Language Action Therapy

Sponsors

National Institute on Deafness and Other Communication Disorders (NIDCD)
CollaboratorNIH
University of Massachusetts, Amherst
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
21 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* unilateral left hemisphere stroke at least 6 months earlier * aphasia with moderate-to-severe word retrieval impairments * at least 21 years of age * premorbidly right handed * native speaker of English

Exclusion criteria

* history of developmental learning difficulties * history of prior neurological illnesses * chronic medical illnesses that restrict participation in intensive therapy * recent alcohol or drug dependence * severe uncorrected impairments of vision or hearing * any contraindication to a 3T MRI procedure (e.g., claustrophobia, metal implants or fragments in body, pregnancy)

Design outcomes

Primary

MeasureTime frame
• Change from baseline on Confrontation Naming TaskChange will be assessed immediately post-treatment (2 weeks)

Secondary

MeasureTime frame
Change from baseline Boston Diagnostic Aphasia ExaminationChange will be assessed immediately post-treatment (2 weeks)

Other

MeasureTime frame
Change from baseline Boston Naming TestChange will be assessed immediately post-treatment (2 weeks)
Change from baseline discourse samplesChange will be assessed post-home practice program (approx. 6 months)
Change from baseline Assessment of Living with AphasiaChange will be assessed post-home practice program (approx. 6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026